GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Cyclically Adjusted Book per Share

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Cyclically Adjusted Book per Share : $6.14 (As of Sep. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Intercept Pharmaceuticals's adjusted book value per share for the three months ended in Sep. 2023 was $1.718. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.14 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Intercept Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-05), Intercept Pharmaceuticals's current stock price is $19.00. Intercept Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $6.14. Intercept Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 3.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Intercept Pharmaceuticals was 4.76. The lowest was 1.63. And the median was 2.47.


Intercept Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Intercept Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Cyclically Adjusted Book per Share Chart

Intercept Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 7.41 6.72 6.26

Intercept Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.34 6.26 6.29 6.20 6.14

Competitive Comparison of Intercept Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Intercept Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intercept Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Intercept Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intercept Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=1.718/129.8595*129.8595
=1.718

Current CPI (Sep. 2023) = 129.8595.

Intercept Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 4.250 98.326 5.613
201403 -7.857 99.695 -10.234
201406 13.690 100.560 17.679
201409 12.243 100.428 15.831
201412 10.782 99.070 14.133
201503 17.436 99.621 22.728
201506 29.936 100.684 38.611
201509 27.948 100.392 36.152
201512 24.687 99.792 32.125
201603 19.856 100.470 25.664
201606 16.886 101.688 21.564
201609 16.738 101.861 21.339
201612 12.689 101.863 16.177
201703 9.605 102.862 12.126
201706 6.761 103.349 8.495
201709 4.449 104.136 5.548
201712 0.651 104.011 0.813
201803 -2.064 105.290 -2.546
201806 4.958 106.317 6.056
201809 3.231 106.507 3.939
201812 0.644 105.998 0.789
201903 -1.847 107.251 -2.236
201906 5.358 108.070 6.438
201909 3.994 108.329 4.788
201912 1.569 108.420 1.879
202003 -1.054 108.902 -1.257
202006 -2.389 108.767 -2.852
202009 -3.949 109.815 -4.670
202012 -5.054 109.897 -5.972
202103 -6.032 111.754 -7.009
202106 -6.120 114.631 -6.933
202109 -5.281 115.734 -5.926
202112 -6.221 117.630 -6.868
202203 -12.513 121.301 -13.396
202206 -12.411 125.017 -12.892
202209 2.600 125.227 2.696
202212 2.242 125.222 2.325
202303 1.612 127.348 1.644
202306 1.617 128.729 1.631
202309 1.718 129.860 1.718

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Intercept Pharmaceuticals  (NAS:ICPT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Intercept Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=19.00/6.14
=3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Intercept Pharmaceuticals was 4.76. The lowest was 1.63. And the median was 2.47.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Intercept Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercept Pharmaceuticals (Intercept Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
305 Madison Avenue, Morristown, NJ, USA, 07960
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandip Kapadia officer: CFO and Treasurer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jason Campagna officer: Chief Medical Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Francesco Micheli 10 percent owner C/O GENEXTRA S.P.A., VIA G. DE GRASSI, 11, MILAN L6 20124
Genextra S.p.a. 10 percent owner VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Headlines

From GuruFocus